Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Group ACYW135X Meningococcal Conjugate Vaccine in individuals aged 2-59 years
NCT07374510Phase 1Not yet recruiting
- Sponsor
- Sinovac Life Sciences
- Start
- Jan 2026
- Primary completion
- Sep 2026
- Modality
- Vaccines & Immunotherapeutics
01
Overview
Phase 1, randomised, single-blind trial of ACYW135X meningococcal conjugate vaccine in meningococcal meningitis (5 arms), sponsored by Sinovac Life Sciences. Primary endpoint: Adverse Reactions at 30 days. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
ACYW135X meningococcal conjugate vaccine
03
Conditions
meningococcal meningitis
Beyond the preview
Go deeper on NCT07374510.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07374510.